<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36208907</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2162-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>International review of neurobiology</Title><ISOAbbreviation>Int Rev Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>89</EndPage><MedlinePgn>63-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/bs.irn.2022.04.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0074-7742(22)00033-2</ELocationID><Abstract><AbstractText>The Coronavirus Disease 2019 (Covid-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has led to unprecedented challenges for the delivery of healthcare and has had a clear impact on people with chronic neurological conditions such as Parkinson's disease (PD). Acute worsening of motor and non-motor symptoms and long-term sequalae have been described during and after SARS-CoV-2 infections in people with Parkinson's (PwP), which are likely to be multifactorial in their origin. On the one hand, it is likely that worsening of symptoms has been related to the viral infection itself, whereas social restrictions imposed over the course of the Covid-19 pandemic might also have had such an effect. Twenty cases of post-Covid-19 para-infectious or post-infectious parkinsonism have been described so far where a variety of pathophysiological mechanisms seem to be involved; however, a Covid-19-induced wave of post-viral parkinsonism seems rather unlikely at the moment. Here, we describe the interaction between SARS-CoV-2 and PD in the short- and long-term and summarize the clinical features of post-Covid-19 cases of parkinsonism observed so far.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leta</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Institute of Psychiatry, Psychology &amp;amp; Neuroscience, King's College London, London, United Kingdom; Parkinson's Foundation Centre of Excellence, King's College Hospital NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boura</LastName><ForeName>Iro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Institute of Psychiatry, Psychology &amp;amp; Neuroscience, King's College London, London, United Kingdom; Parkinson's Foundation Centre of Excellence, King's College Hospital NHS Foundation Trust, London, United Kingdom; Medical School, University of Crete, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Wamelen</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Institute of Psychiatry, Psychology &amp;amp; Neuroscience, King's College London, London, United Kingdom; Parkinson's Foundation Centre of Excellence, King's College Hospital NHS Foundation Trust, London, United Kingdom; Department of Neurology, Centre of Expertise for Parkinson &amp;amp; Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Violante</LastName><ForeName>Mayela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Neurologia y Neurocirugia, Ciudad de M&#xe9;xico, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonini</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Parkinson and Movement Disorders Unit, Department of Neuroscience, Centre for Rare Neurological Diseases (ERN-RND), University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaudhuri</LastName><ForeName>Kallol Ray</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Institute of Psychiatry, Psychology &amp;amp; Neuroscience, King's College London, London, United Kingdom; Parkinson's Foundation Centre of Excellence, King's College Hospital NHS Foundation Trust, London, United Kingdom. Electronic address: ray.chaudhuri@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int Rev Neurobiol</MedlineTA><NlmUniqueID>0374740</NlmUniqueID><ISSNLinking>0074-7742</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="Y">Parkinsonian Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Motor symptoms</Keyword><Keyword MajorTopicYN="N">Non-motor symptoms</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">Parkinsonism</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>8</Day><Hour>21</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36208907</ArticleId><ArticleId IdType="pmc">PMC9357514</ArticleId><ArticleId IdType="doi">10.1016/bs.irn.2022.04.004</ArticleId><ArticleId IdType="pii">S0074-7742(22)00033-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ait Wahmane S., Achbani A., Ouhaz Z., Elatiqi M., Belmouden A., Nejmeddine M. The possible protective role of &#x3b1;-Synuclein against severe acute respiratory syndrome coronavirus 2 infections in patients with Parkinson's disease. Movement Disorders. 2020;35(8):1293&#x2013;1294. doi: 10.1002/mds.28185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28185</ArticleId><ArticleId IdType="pmc">PMC7300655</ArticleId><ArticleId IdType="pubmed">32519352</ArticleId></ArticleIdList></Reference><Reference><Citation>Akilli N.B., Yosunkaya A. Part of the Covid19 puzzle: Acute parkinsonism. The American Journal of Emergency Medicine. 2021;47:333.e331&#x2013;333.e333. doi: 10.1016/j.ajem.2021.02.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2021.02.050</ArticleId><ArticleId IdType="pmc">PMC7903921</ArticleId><ArticleId IdType="pubmed">33712341</ArticleId></ArticleIdList></Reference><Reference><Citation>Amiri-Dashatan N., Koushki M., Parsamanesh N., Chiti H. Serum cortisol concentration and COVID-19 severity: A systematic review and meta-analysis. Journal of Investigative Medicine. 2022 doi: 10.1136/jim-2021-001989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-001989</ArticleId><ArticleId IdType="pubmed">35058334</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonini A., Leta V., Teo J., Chaudhuri K.R. Outcome of Parkinson's disease patients affected by COVID-19. Movement Disorders. 2020;35(6):905&#x2013;908. doi: 10.1002/mds.28104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28104</ArticleId><ArticleId IdType="pmc">PMC7267273</ArticleId><ArticleId IdType="pubmed">32347572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ara&#xfa;jo R., Aranda-Mart&#xed;nez J.D., Aranda-Abreu G.E. Amantadine treatment for people with COVID-19. Archives of Medical Research. 2020;51(7):739&#x2013;740. doi: 10.1016/j.arcmed.2020.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.06.009</ArticleId><ArticleId IdType="pmc">PMC7290190</ArticleId><ArticleId IdType="pubmed">32571606</ArticleId></ArticleIdList></Reference><Reference><Citation>Artusi C.A., Romagnolo A., Imbalzano G., Marchet A., Zibetti M., Rizzone M.G., et al. COVID-19 in Parkinson's disease: Report on prevalence and outcome. Parkinsonism &amp; Related Disorders. 2020;80:7&#x2013;9. doi: 10.1016/j.parkreldis.2020.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2020.09.008</ArticleId><ArticleId IdType="pmc">PMC7474816</ArticleId><ArticleId IdType="pubmed">32920322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayele B.A., Demissie H., Awraris M., Amogne W., Shalash A., Ali K., et al. SARS-COV-2 induced parkinsonism: The first case from the sub-Saharan Africa. Clinical Parkinsonism &amp; Related Disorders. 2021;5:100116. doi: 10.1016/j.prdoa.2021.100116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prdoa.2021.100116</ArticleId><ArticleId IdType="pmc">PMC8582125</ArticleId><ArticleId IdType="pubmed">34786554</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchamp L.C., Finkelstein D.I., Bush A.I., Evans A.H., Barnham K.J. Parkinsonism as a third wave of the COVID-19 pandemic? Journal of Parkinson's Disease. 2020;10(4):1343&#x2013;1353. doi: 10.3233/JPD-202211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-202211</ArticleId><ArticleId IdType="pmc">PMC7683045</ArticleId><ArticleId IdType="pubmed">32986683</ArticleId></ArticleIdList></Reference><Reference><Citation>Boika A.V., Sialitski M.M., Chyzhyk V.A., Ponomarev V.V., Fomina E.G. Post-COVID worsening of a Parkinson's disease patient. Clinical Case Reports. 2021;9(7) doi: 10.1002/ccr3.4409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.4409</ArticleId><ArticleId IdType="pmc">PMC8259921</ArticleId><ArticleId IdType="pubmed">34257979</ArticleId></ArticleIdList></Reference><Reference><Citation>Bopeththa B., Ralapanawa U. Post encephalitic parkinsonism following dengue viral infection. BMC Research Notes. 2017;10(1):655. doi: 10.1186/s13104-017-2954-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-017-2954-5</ArticleId><ArticleId IdType="pmc">PMC5708097</ArticleId><ArticleId IdType="pubmed">29187231</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen D.P., Vuono R., Nawarathna U., Fisher K., Shneerson J.M., Reddy A.B., et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurology. 2014;71(5):589&#x2013;595. doi: 10.1001/jamaneurol.2014.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.65</ArticleId><ArticleId IdType="pmc">PMC4119609</ArticleId><ArticleId IdType="pubmed">24687146</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown E.G., Chahine L.M., Goldman S.M., Korell M., Mann E., Kinel D.R., et al. The effect of the COVID-19 pandemic on people with Parkinson's disease. Journal of Parkinson's Disease. 2020;10(4):1365&#x2013;1377. doi: 10.3233/jpd-202249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jpd-202249</ArticleId><ArticleId IdType="pmc">PMC7683050</ArticleId><ArticleId IdType="pubmed">32925107</ArticleId></ArticleIdList></Reference><Reference><Citation>Brugger F., Erro R., Balint B., K&#xe4;gi G., Barone P., Bhatia K.P. Why is there motor deterioration in Parkinson's disease during systemic infections-a hypothetical view. NPJ Parkinson's Disease. 2015;1:15014. doi: 10.1038/npjparkd.2015.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npjparkd.2015.14</ArticleId><ArticleId IdType="pmc">PMC5516617</ArticleId><ArticleId IdType="pubmed">28725683</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P., Nath A., Beckham J.D. Is COVID-19 a perfect storm for Parkinson's disease? Trends in Neurosciences. 2020;43(12):931&#x2013;933. doi: 10.1016/j.tins.2020.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.10.009</ArticleId><ArticleId IdType="pmc">PMC7577682</ArticleId><ArticleId IdType="pubmed">33158605</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallieri F., Fioravanti V., Toschi G., Grisanti S., Napoli M., Moratti C., et al. COVID-19 and Parkinson's disease: A casual association or a possible second hit in neurodegeneration? Journal of Neurology. 2021;1&#x2013;3 doi: 10.1007/s00415-021-10694-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10694-4</ArticleId><ArticleId IdType="pmc">PMC8254452</ArticleId><ArticleId IdType="pubmed">34216264</ArticleId></ArticleIdList></Reference><Reference><Citation>Cilia R., Bonvegna S., Straccia G., Andreasi N.G., Elia A.E., Romito L.M., et al. Effects of COVID-19 on Parkinson's disease clinical features: A community-based case-control study. Movement Disorders. 2020;35(8):1287&#x2013;1292. doi: 10.1002/mds.28170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28170</ArticleId><ArticleId IdType="pmc">PMC7280741</ArticleId><ArticleId IdType="pubmed">32449528</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark A.J., Ritz B., Prescott E., Rod N.H. Psychosocial risk factors, pre-motor symptoms and first-time hospitalization with Parkinson's disease: A prospective cohort study. European Journal of Neurology. 2013;20(8):1113&#x2013;1120. doi: 10.1111/ene.12117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12117</ArticleId><ArticleId IdType="pmc">PMC3664243</ArticleId><ArticleId IdType="pubmed">23433314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M.E., Eichel R., Steiner-Birmanns B., Janah A., Ioshpa M., Bar-Shalom R., et al. A case of probable Parkinson's disease after SARS-CoV-2 infection. Lancet Neurology. 2020;19(10):804&#x2013;805. doi: 10.1016/s1474-4422(20)30305-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(20)30305-7</ArticleId><ArticleId IdType="pmc">PMC7494295</ArticleId><ArticleId IdType="pubmed">32949534</ArticleId></ArticleIdList></Reference><Reference><Citation>Daley D.J., Deane K.H., Gray R.J., Hill R., Myint P.K. Qualitative evaluation of adherence therapy in Parkinson's disease: A multidirectional model. Patient Preference and Adherence. 2015;9:989&#x2013;998. doi: 10.2147/ppa.S80158.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ppa.S80158</ArticleId><ArticleId IdType="pmc">PMC4508072</ArticleId><ArticleId IdType="pubmed">26203231</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souza A. Movement disorders and the osmotic demyelination syndrome. Parkinsonism &amp; Related Disorders. 2013;19(8):709&#x2013;716. doi: 10.1016/j.parkreldis.2013.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2013.04.005</ArticleId><ArticleId IdType="pubmed">23660544</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Prete E., Francesconi A., Palermo G., Mazzucchi S., Frosini D., Morganti R., et al. Prevalence and impact of COVID-19 in Parkinson's disease: Evidence from a multi-center survey in Tuscany region. Journal of Neurology. 2021;268(4):1179&#x2013;1187. doi: 10.1007/s00415-020-10002-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10002-6</ArticleId><ArticleId IdType="pmc">PMC7471534</ArticleId><ArticleId IdType="pubmed">32880722</ArticleId></ArticleIdList></Reference><Reference><Citation>Djamshidian A., O'Sullivan S.S., Papadopoulos A., Bassett P., Shaw K., Averbeck B.B., et al. Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour. Journal of Neurology, Neurosurgery, and Psychiatry. 2011;82(10):1107&#x2013;1111. doi: 10.1136/jnnp.2011.245746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2011.245746</ArticleId><ArticleId IdType="pmc">PMC3171980</ArticleId><ArticleId IdType="pubmed">21478206</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul M.A., Benjamin L., Singh B., Lant S., Michael B.D., Easton A., et al. Neurological associations of COVID-19. The Lancet Neurology. 2020;19(9):767&#x2013;783. doi: 10.1016/S1474-4422(20)30221-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30221-0</ArticleId><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Faber I., Brand&#xe3;o P.R.P., Menegatti F., de Carvalho Bispo D.D., Maluf F.B., Cardoso F. Coronavirus disease 2019 and parkinsonism: A non-post-encephalitic case. Movement Disorders. 2020;35(10):1721&#x2013;1722. doi: 10.1002/mds.28277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28277</ArticleId><ArticleId IdType="pmc">PMC7461093</ArticleId><ArticleId IdType="pubmed">32815213</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearon C., Fasano A. Parkinson's disease and the COVID-19 pandemic. Journal of Parkinson's Disease. 2021;11(2):431&#x2013;444. doi: 10.3233/jpd-202320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jpd-202320</ArticleId><ArticleId IdType="pmc">PMC8150477</ArticleId><ArticleId IdType="pubmed">33492244</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearon C., Mikulis D.J., Lang A.E. Parkinsonism as a sequela of SARS-CoV-2 infection: Pure hypoxic injury or additional COVID-19-related response? Movement Disorders. 2021;36(7):1483&#x2013;1484. doi: 10.1002/mds.28656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28656</ArticleId><ArticleId IdType="pmc">PMC8242400</ArticleId><ArticleId IdType="pubmed">34043246</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger J.C., Miller A.H. Cytokine effects on the basal ganglia and dopamine function: The subcortical source of inflammatory malaise. Frontiers in Neuroendocrinology. 2012;33(3):315&#x2013;327. doi: 10.1016/j.yfrne.2012.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2012.09.003</ArticleId><ArticleId IdType="pmc">PMC3484236</ArticleId><ArticleId IdType="pubmed">23000204</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger J.C., Mun J., Kimmel H.L., Nye J.A., Drake D.F., Hernandez C.R., et al. Chronic interferon-&#x3b1; decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology. 2013;38(11):2179&#x2013;2187. doi: 10.1038/npp.2013.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2013.115</ArticleId><ArticleId IdType="pmc">PMC3773667</ArticleId><ArticleId IdType="pubmed">23657438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlach O.H., Broen M.P., Weber W.E. Motor outcomes during hospitalization in Parkinson's disease patients: A prospective study. Parkinsonism &amp; Related Disorders. 2013;19(8):737&#x2013;741. doi: 10.1016/j.parkreldis.2013.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2013.04.017</ArticleId><ArticleId IdType="pubmed">23680419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh R., Ray A., Roy D., Das S., Dubey S., Benito-Le&#xf3;n J. Parkinsonism with akinetic mutism following osmotic demyelination syndrome in a SARS-CoV-2 infected elderly diabetic woman: A case report. Neurolog&#xed;a. 2021 doi: 10.1016/j.nrl.2021.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nrl.2021.09.007</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowers W.R. A manual of diseases of the nervous system. The American Journal of Psychology. 1888;1(2):346&#x2013;347. doi: 10.2307/1411377.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/1411377</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan J., Lu Z., Zhou Q. Reversible parkinsonism due to involvement of substantia nigra in Epstein-Barr virus encephalitis. Movement Disorders. 2012;27(1):156&#x2013;157. doi: 10.1002/mds.23935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23935</ArticleId><ArticleId IdType="pubmed">21989835</ArticleId></ArticleIdList></Reference><Reference><Citation>Hainque E., Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection. Parkinsonism &amp; Related Disorders. 2020;75:126&#x2013;127. doi: 10.1016/j.parkreldis.2020.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7205634</ArticleId><ArticleId IdType="pubmed">32414669</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes C.H., Del Tredici K., Braak H. Parkinson's disease: A dual-hit hypothesis. Neuropathology and Applied Neurobiology. 2007;33(6):599&#x2013;614. doi: 10.1111/j.1365-2990.2007.00874.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2007.00874.x</ArticleId><ArticleId IdType="pmc">PMC7194308</ArticleId><ArticleId IdType="pubmed">17961138</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry J., Smeyne R.J., Jang H., Miller B., Okun M.S. Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism &amp; Related Disorders. 2010;16(9):566&#x2013;571. doi: 10.1016/j.parkreldis.2010.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2010.06.012</ArticleId><ArticleId IdType="pmc">PMC4684089</ArticleId><ArticleId IdType="pubmed">20650672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman L.A., Vilensky J.A. Encephalitis lethargica: 100 years after the epidemic. Brain. 2017;140(8):2246&#x2013;2251. doi: 10.1093/brain/awx177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx177</ArticleId><ArticleId IdType="pubmed">28899018</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo L., Xu K.L., Wang H. Clinical features of SARS-CoV-2-associated encephalitis and meningitis amid COVID-19 pandemic. World Journal of Clinical Cases. 2021;9(5):1058&#x2013;1078. doi: 10.12998/wjcc.v9.i5.1058.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v9.i5.1058</ArticleId><ArticleId IdType="pmc">PMC7896657</ArticleId><ArticleId IdType="pubmed">33644169</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H., Boltz D.A., Webster R.G., Smeyne R.J. Viral parkinsonism. Biochimica et Biophysica Acta. 2009;1792(7):714&#x2013;721. doi: 10.1016/j.bbadis.2008.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2008.08.001</ArticleId><ArticleId IdType="pmc">PMC4642437</ArticleId><ArticleId IdType="pubmed">18760350</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazumori H., Ishihara S., Rumi M.A., Ortega-Cava C.F., Kadowaki Y., Kinoshita Y. Transforming growth factor-alpha directly augments histidine decarboxylase and vesicular monoamine transporter 2 production in rat enterochromaffin-like cells. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2004;286(3):G508&#x2013;G514. doi: 10.1152/ajpgi.00269.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00269.2003</ArticleId><ArticleId IdType="pubmed">14563668</ArticleId></ArticleIdList></Reference><Reference><Citation>Leta V., Rodr&#xed;guez-Violante M., Abundes A., Rukavina K., Teo J.T., Falup-Pecurariu C., et al. Parkinson's disease and post-COVID-19 syndrome: The Parkinson's long-COVID Spectrum. Movement Disorders. 2021;36(6):1287&#x2013;1289. doi: 10.1002/mds.28622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28622</ArticleId><ArticleId IdType="pmc">PMC8250675</ArticleId><ArticleId IdType="pubmed">33890344</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis A., Frontera J., Placantonakis D.G., Lighter J., Galetta S., Balcer L., et al. Cerebrospinal fluid in COVID-19: A systematic review of the literature. Journal of the Neurological Sciences. 2021;421 doi: 10.1016/j.jns.2021.117316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117316</ArticleId><ArticleId IdType="pmc">PMC7833669</ArticleId><ArticleId IdType="pubmed">33561753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi A., Domingues R., Setz C., Outeiro T.F., Krisko A. SARS-CoV-2: At the crossroad between aging and neurodegeneration. Movement Disorders. 2020;35(5):716&#x2013;720. doi: 10.1002/mds.28084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28084</ArticleId><ArticleId IdType="pmc">PMC7262312</ArticleId><ArticleId IdType="pubmed">32291797</ArticleId></ArticleIdList></Reference><Reference><Citation>Luis-Mart&#xed;nez R., Di Marco R., Weis L., Cianci V., Pistonesi F., Baba A., et al. Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown. BMC Neurology. 2021;21(1):332. doi: 10.1186/s12883-021-02364-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-021-02364-9</ArticleId><ArticleId IdType="pmc">PMC8404403</ArticleId><ArticleId IdType="pubmed">34461838</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhoul K., Jankovic J. Parkinson's disease after COVID-19. Journal of the Neurological Sciences. 2021;422 doi: 10.1016/j.jns.2021.117331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117331</ArticleId><ArticleId IdType="pmc">PMC9755718</ArticleId><ArticleId IdType="pubmed">33540185</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;ndez-Guerrero A., Laespada-Garc&#xed;a M.I., G&#xf3;mez-Grande A., Ruiz-Ortiz M., Blanco-Palmero V.A., Azcarate-Diaz F.J., et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology. 2020;95(15):e2109&#x2013;e2118. doi: 10.1212/wnl.0000000000010282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000010282</ArticleId><ArticleId IdType="pubmed">32641525</ArticleId></ArticleIdList></Reference><Reference><Citation>Merello M., Bhatia K.P., Obeso J.A. SARS-CoV-2 and the risk of Parkinson's disease: Facts and fantasy. Lancet Neurology. 2021;20(2):94&#x2013;95. doi: 10.1016/s1474-4422(20)30442-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(20)30442-7</ArticleId><ArticleId IdType="pmc">PMC7834123</ArticleId><ArticleId IdType="pubmed">33253627</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore H., Rose H.J., Grace A.A. Chronic cold stress reduces the spontaneous activity of ventral tegmental dopamine neurons. Neuropsychopharmacology. 2001;24(4):410&#x2013;419. doi: 10.1016/s0893-133x(00)00188-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0893-133x(00)00188-3</ArticleId><ArticleId IdType="pubmed">11182536</ArticleId></ArticleIdList></Reference><Reference><Citation>Morassi M., Palmerini F., Nici S., Magni E., Savelli G., Guerra U.P., et al. SARS-CoV-2-related encephalitis with prominent parkinsonism: Clinical and FDG-PET correlates in two patients. Journal of Neurology. 2021;1&#x2013;8 doi: 10.1007/s00415-021-10560-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10560-3</ArticleId><ArticleId IdType="pmc">PMC8059684</ArticleId><ArticleId IdType="pubmed">33884450</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller T., Muhlack S. Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease. Clinical Neuropharmacology. 2007;30(2):101&#x2013;106. doi: 10.1097/01.wnf.0000240954.72186.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wnf.0000240954.72186.91</ArticleId><ArticleId IdType="pubmed">17414942</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataf S. An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. Journal of Medical Virology. 2020;92(10):1743&#x2013;1744. doi: 10.1002/jmv.25826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25826</ArticleId><ArticleId IdType="pmc">PMC7228370</ArticleId><ArticleId IdType="pubmed">32246784</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann B., Schmidbauer M.L., Dimitriadis K., Otto S., Knier B., Niesen W.D., et al. Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. Journal of the Neurological Sciences. 2020;418 doi: 10.1016/j.jns.2020.117090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117090</ArticleId><ArticleId IdType="pmc">PMC7417278</ArticleId><ArticleId IdType="pubmed">32805440</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen N.N., Hoang V.T., Dao T.L., Dudouet P., Eldin C., Gautret P. Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: A systematic review. European Journal of Clinical Microbiology &amp; Infectious Diseases. 2022;1-31 doi: 10.1007/s10096-022-04417-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-022-04417-4</ArticleId><ArticleId IdType="pmc">PMC8830952</ArticleId><ArticleId IdType="pubmed">35142947</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE . National Institute for Health and Care Excellence (NICE); London: 2020. COVID-19 rapid guideline: Managing the long-term effects of COVID-19.https://pubmed.ncbi.nlm.nih.gov/33555768/</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura T., Ito R., Ishiguro N., Tamai I., Deguchi Y. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sciences. 2007;80(17):1564&#x2013;1571. doi: 10.1016/j.lfs.2007.01.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2007.01.035</ArticleId><ArticleId IdType="pubmed">17307202</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong T.L., Nor K.M., Yusoff Y., Sapuan S. COVID-19 associated acute necrotizing encephalopathy presenting as parkinsonism and Myorhythmia. Journal of Movement Disorders. 2022;15(1):89&#x2013;92. doi: 10.14802/jmd.21063.</Citation><ArticleIdList><ArticleId IdType="doi">10.14802/jmd.21063</ArticleId><ArticleId IdType="pmc">PMC8820880</ArticleId><ArticleId IdType="pubmed">34781632</ArticleId></ArticleIdList></Reference><Reference><Citation>Onofrj M., Bonanni L., Cossu G., Manca D., Stocchi F., Thomas A. Emergencies in parkinsonism: Akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism &amp; Related Disorders. 2009;15(Suppl 3):S233&#x2013;S236. doi: 10.1016/s1353-8020(09)70821-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1353-8020(09)70821-1</ArticleId><ArticleId IdType="pubmed">20082998</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A., Masciocchi S., Volonghi I., Crabbio M., Magni E., De Giuli V., et al. Clinical presentation and outcomes of severe acute respiratory syndrome coronavirus 2-related encephalitis: The ENCOVID multicenter study. The Journal of Infectious Diseases. 2021;223(1):28&#x2013;37. doi: 10.1093/infdis/jiaa609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa609</ArticleId><ArticleId IdType="pmc">PMC7543535</ArticleId><ArticleId IdType="pubmed">32986824</ArticleId></ArticleIdList></Reference><Reference><Citation>Pissadaki E.K., Bolam J.P. The energy cost of action potential propagation in dopamine neurons: Clues to susceptibility in Parkinson's disease. Frontiers in Computational Neuroscience. 2013;7:13. doi: 10.3389/fncom.2013.00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncom.2013.00013</ArticleId><ArticleId IdType="pmc">PMC3600574</ArticleId><ArticleId IdType="pubmed">23515615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao A.R., Hidayathullah S.M., Hegde K., Adhikari P. Parkinsonism: An emerging post COVID sequelae. IDCases. 2022;27 doi: 10.1016/j.idcr.2022.e01388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2022.e01388</ArticleId><ArticleId IdType="pmc">PMC8733235</ArticleId><ArticleId IdType="pubmed">35018281</ArticleId></ArticleIdList></Reference><Reference><Citation>Rass V., Beer R., Schiefecker A.J., Kofler M., Lindner A., Mahlknecht P., et al. Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. European Journal of Neurology. 2021;28(10):3348&#x2013;3359. doi: 10.1111/ene.14803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14803</ArticleId><ArticleId IdType="pmc">PMC8250725</ArticleId><ArticleId IdType="pubmed">33682276</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy D., Song J., Awad N., Zamudio P. Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19. BML Case Reports. 2021;14(3) doi: 10.1136/bcr-2020-239781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-239781</ArticleId><ArticleId IdType="pmc">PMC7929831</ArticleId><ArticleId IdType="pubmed">33653852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzicka F., Jech R., Novakova L., Urgosik D., Bezdicek O., Vymazal J., et al. Chronic stress-like syndrome as a consequence of medial site subthalamic stimulation in Parkinson's disease. Psychoneuroendocrinology. 2015;52:302&#x2013;310. doi: 10.1016/j.psyneuen.2014.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2014.12.001</ArticleId><ArticleId IdType="pubmed">25554999</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Garc&#xed;a D., Oreiro M., P&#xe9;rez P., Fanjul G., Paz Gonz&#xe1;lez J.M., Feal Painceiras M.J., et al. Impact of coronavirus disease 2019 pandemic on Parkinson's disease: A cross-sectional survey of 568 Spanish patients. Movement Disorders. 2020;35(10):1712&#x2013;1716. doi: 10.1002/mds.28261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28261</ArticleId><ArticleId IdType="pmc">PMC7436468</ArticleId><ArticleId IdType="pubmed">32776601</ArticleId></ArticleIdList></Reference><Reference><Citation>Siow I., Lee K.S., Zhang J.J.Y., Saffari S.E., Ng A. Encephalitis as a neurological complication of COVID-19: A systematic review and meta-analysis of incidence, outcomes, and predictors. European Journal of Neurology. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239820</ArticleId><ArticleId IdType="pubmed">33982853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonneville R., Klein I., de Broucker T., Wolff M. Post-infectious encephalitis in adults: Diagnosis and management. The Journal of Infection. 2009;58(5):321&#x2013;328. doi: 10.1016/j.jinf.2009.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2009.02.011</ArticleId><ArticleId IdType="pmc">PMC7125543</ArticleId><ArticleId IdType="pubmed">19368974</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends in Neurosciences. 2007;30(5):244&#x2013;250. doi: 10.1016/j.tins.2007.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2007.03.009</ArticleId><ArticleId IdType="pubmed">17418429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P., Xhani R., Zerbi S.M., Corso A., Martinelli I., Fusi L., et al. Postinfectious neurologic complications in COVID-19: A complex case report. Journal of Nuclear Medicine. 2021;62(8):1171&#x2013;1176. doi: 10.2967/jnumed.120.256099.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.120.256099</ArticleId><ArticleId IdType="pmc">PMC8833873</ArticleId><ArticleId IdType="pubmed">34016729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufekci K.U., Meuwissen R., Genc S., Genc K. Inflammation in Parkinson's disease. Advances in Protein Chemistry and Structural Biology. 2012;88:69&#x2013;132. doi: 10.1016/b978-0-12-398314-5.00004-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-398314-5.00004-0</ArticleId><ArticleId IdType="pubmed">22814707</ArticleId></ArticleIdList></Reference><Reference><Citation>Tysnes O.B., Storstein A. Epidemiology of Parkinson's disease. Journal of Neural Transmission (Vienna) 2017;124(8):901&#x2013;905. doi: 10.1007/s00702-017-1686-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1686-y</ArticleId><ArticleId IdType="pubmed">28150045</ArticleId></ArticleIdList></Reference><Reference><Citation>Umemura A., Oeda T., Tomita S., Hayashi R., Kohsaka M., Park K., et al. Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: A nested case-control study. PLoS One. 2014;9(6) doi: 10.1371/journal.pone.0094944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094944</ArticleId><ArticleId IdType="pmc">PMC4041721</ArticleId><ArticleId IdType="pubmed">24887491</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wamelen D.J., Wan Y.-M., Chaudhuri K.R., Jenner P. Stress and cortisol in Parkinson's disease. International Review of Neurobiology. 2020;152:131&#x2013;156. doi: 10.1016/bs.irn.2020.01.005. https://pubmed.ncbi.nlm.nih.gov/32450994/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.irn.2020.01.005</ArticleId><ArticleId IdType="pubmed">32450994</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan D., Du T., Hong W., Chen L., Que H., Lu S., et al. Neurological complications and infection mechanism of SARS-COV-2. Signal Transduction and Targeted Therapy. 2021;6(1):406. doi: 10.1038/s41392-021-00818-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00818-7</ArticleId><ArticleId IdType="pmc">PMC8609271</ArticleId><ArticleId IdType="pubmed">34815399</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A., Branscome H., Khatkar P., Mensah G.A., Al Sharif S., Pinto D.O., et al. A comprehensive review of COVID-19 biology, diagnostics, therapeutics, and disease impacting the central nervous system. Journal of Neurovirology. 2021;27(5):667&#x2013;690. doi: 10.1007/s13365-021-00998-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00998-6</ArticleId><ArticleId IdType="pmc">PMC8477646</ArticleId><ArticleId IdType="pubmed">34581996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood H. New insights into the neurological effects of COVID-19. Nature Reviews. Neurology. 2020;16(8):403. doi: 10.1038/s41582-020-0386-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0386-7</ArticleId><ArticleId IdType="pmc">PMC7317889</ArticleId><ArticleId IdType="pubmed">32591754</ArticleId></ArticleIdList></Reference><Reference><Citation>Worldmeter.info COVID-19 coronavirus pandemic. 2021. https://www.worldometers.info/coronavirus/ Retrieved from. 24/10/2021.</Citation></Reference><Reference><Citation>Wu X., Wu W., Pan W., Wu L., Liu K., Zhang H.-L. Acute necrotizing encephalopathy: An underrecognized clinicoradiologic disorder. Mediators of Inflammation. 2015;2015:792578&#x2013;792587. doi: 10.1155/2015/792578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/792578</ArticleId><ArticleId IdType="pmc">PMC4385702</ArticleId><ArticleId IdType="pubmed">25873770</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing F., Marsili L., Truong D.D. Parkinsonism in viral, paraneoplastic, and autoimmune diseases. Journal of the Neurological Sciences. 2022;433 doi: 10.1016/j.jns.2021.120014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.120014</ArticleId><ArticleId IdType="pubmed">34629181</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>